Selegiline (Selegiline Hydrochloride) - Indications and Dosage

INDICATIONS AND USAGE

Selegiline hydrochloride is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy.

Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).

DOSAGE AND ADMINISTRATION

Selegiline hydrochloride is intended for administration to Parkinsonian patients receiving levodopa/carbidopa therapy who demonstrate a deteriorating response to this treatment. The recommended regimen for the administration of selegiline hydrochloride is 10 mg per day administered as divided doses of 5 mg each taken at breakfast and lunch. There is no evidence that additional benefit will be obtained from the administration of higher doses. Moreover, higher doses should ordinarily be avoided because of the increased risk of side effects.

After two to three days of selegiline treatment, an attempt may be made to reduce the dose of levodopa/carbidopa. A reduction of 10 to 30% was achieved with the typical participant in the domestic placebo controlled trials who was assigned to selegiline treatment. Further reductions of levodopa/carbidopa may be possible during continued selegiline therapy.

HOW SUPPLIED

Selegiline Hydrochloride Tablets, USP are supplied as follows:

5 mg – white, oval tablets; debossed with “Endo” on one side and plain on the other.

Bottles of 60
NDC 60951-620-60

Bottles of 500
NDC 60951-620-85

Store at controlled room temperature, 15°-30°C (59°-86°F). Dispense in a tight, light-resistant container, as defined in the USP, with a child-resistant closure (as required).

Manufactured for:
Endo Pharmaceuticals Inc.
Chadds Ford, Pennsylvania 19317

Copyright © Endo Pharmaceuticals Inc. 2003

Printed in U.S.A.                                                                      6383-06/May, 2003